Physician profile
Gina Wang
NPI 1619991510
$4,365.26
in general payments reported to CMS, 2019-2025
32 companies · $587 in 2025
The $587 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $538 · 2021: $624 · 2022: $637 · 2023: $858 · 2024: $555 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $593.62 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $552.63 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $474.97 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $470.60 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $346.71 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $250.87 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $208.74 | 2019-2024 | Repatha |
| Abbvie INC. | $164.72 | 2019-2023 | Viberzi, Linzess, Ubrelvy |
| Sanofi-Aventis U.S. LLC | $115.84 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $114.29 | 2019-2022 | |
| Dexcom, INC. | $101.42 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $95.15 | 2022-2023 | |
| Amarin Pharma, INC. | $90.17 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $78.04 | 2019-2021 | |
| Gilead Sciences, INC. | $73.22 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $68.69 | 2023-2024 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.03 | 2021-2025 | Xifaxan |
| Scilex Pharmaceuticals INC. | $61.31 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $52.28 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $49.40 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $46.59 | 2024-2025 | Gemtesa |
| Sanofi Pasteur INC. | $45.82 | 2019-2023 | |
| Agios Pharmaceuticals, INC. | $32.52 | 2025 | Pyrukynd |
| Exact Sciences Corporation | $30.46 | 2025 | The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $29.22 | 2023 | Nuedexta |
| Astellas Pharma US INC | $27.76 | 2023 | Veozah |
| Kowa Pharmaceuticals America, INC. | $24.94 | 2019 | |
| Abbott Laboratories | $24.84 | 2025 | Mitraclip |
| Recordati_rare_diseases_inc. | $23.40 | 2023 | Signifor Lar, Isturisa |
| Radius Health, INC. | $21.63 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.38 | 2021 | |
| Allergan, INC. | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.